Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–36.

    CAS  Article  Google Scholar 

  2. 2.

    O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018;131:1910–9.

    Article  Google Scholar 

  3. 3.

    Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912–20.

    Article  Google Scholar 

  4. 4.

    Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013;27:362–9.

    CAS  Article  Google Scholar 

  5. 5.

    Kramer I, Stilgenbauer S, Dietrich S, Bottcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood 2017;130:1477–80.

    Article  Google Scholar 

  6. 6.

    van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, et al. Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia—a retrospective analysis from the Chronic Malignancies Working Party of the EBMT. Clin Lymphoma Myeloma Leuk. 2017;17:667–75 e2.

    Article  Google Scholar 

  7. 7.

    Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, et al. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2017;52:552–60.

    CAS  Article  Google Scholar 

  8. 8.

    Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, et al. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2017;178:521–33.

    Article  Google Scholar 

  9. 9.

    Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood 2018;131:2357–66.

    CAS  Article  Google Scholar 

  10. 10.

    Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 2018;132:892–902.

    CAS  Article  Google Scholar 

  11. 11.

    Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a Phase II Pivotal trial. J Clin Oncol. 2018;36:1973–80.

    CAS  Article  Google Scholar 

  12. 12.

    Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, et al. Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. Haematologica 2019;104:e304–e6.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We wish to thank the patients and their families, the local data managers, and physicians and the staff at the EBMT Data Office in Leiden, who made this study possible.

Participating centers not acknowledged by coauthorship

Belgium: Cliniques Universitaires St. Luc, Brussels (A. Ferrant); Czech Republic: Institute of Hematology and Blood Transfusion, Prague (A. Vitek); Finland: Helsinki University Central Hospital, Helsinki (R. Niittyvuopio), Central Hospital, Turku (M. Itala); France: Hopital La Miletrie, Poitiers (F. Guilhot); Germany: Charité, University Hospital Benjamin Franklin, Berlin (L. Uharek), University Hospital, Göttingen (B. Glass), AK St. Georg, Hamburg (N. Schmitz), University Hospital, Hannover (A. Ganser), Department of Medicine II, University Hospital, Kiel (M. Kneba), University Hospital, Münster (M. Stelljes), Deutsche Klinik für Diagnostik, Wiesbaden (R. Schwerdtfeger); Italy: Ospedale Maggiore di Milano, Milano (F. Onida), Istituto Nazionale dei Tumori (P. Corradini); Spain: Hospital St. Creu I St. Pau, Barcelona (R. Martino), Clinica Puerta de Hierro, Madrid (J.A. García-Marco), Hospital Clínico, Salamanca (D. Caballero), Hospital Universitario La Fe, Valencia (M.A. Sanz).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Johannes Schetelig.

Ethics declarations

Conflict of interest

JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Previous presentations: Annual Meeting of the European Society for Blood and Marrow Transplantation at London in 2013 and at Istanbul in 2015.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schetelig, J., Hoek, J., Stilgenbauer, S. et al. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01013-y

Download citation

Search